STAT Stitch Deep Dive Podcast Beyond The Bedside

***STAT Stitch UPDATE*** https://statstitch.etsy.com click the link to buy a shirt to help and support the channel. Instead of asking for free money I am trying to provide you with some value to help me offset some of the cost it takes to run the channel. so if you like the shirt grab one or 4 and spread the word! Welcome to STAT Stitch Deep Dive: Beyond the Bedside, the podcast where nursing knowledge, clinical storytelling, and the realities of nursing school collide. Whether you’re a current nursing student, preparing for boards, or a new nurse navigating your first year at the bedside, this show is designed to give you the mix of insight, clarity, and encouragement you need to succeed in both the classroom and the hospital. Hosted by a trauma nurse and nursing student who’s living the journey alongside you, each episode combines Audio Overviews—broken down into conversational, easy-to-digest lessons—with real-world reflections and practical nursing tips. The goal? To simplify complex concepts and help connect theory to clinical practice. What You’ll Hear on the Podcast: Deep Dives into Nursing Content: From pathophysiology to pharmacology, each overview is presented in a way that feels like you’re sitting down with a mentor who explains not just the “what,” but the “why.” These episodes break down intimidating topics into clear, conversational lessons that stick. Nursing Management Focus: Every content-heavy episode goes beyond theory to explore how you’ll actually manage a patient at the bedside. If it’s pathophysiology, we’ll dive into the nursing management of those manifestations. If it’s pharmacology, we’ll cover nursing considerations, indications, and patient safety. Chronicles from Nursing School: Think of this as a mini audio diary—stories from the trenches of nursing education. From late-night study sessions and clinical rotations to exam wins (and fails), these episodes highlight the challenges, growth, and resilience that every student nurse will relate to. Practical Nursing Tips: Every episode closes with a tip you can immediately apply—whether it’s a study hack, a clinical shortcut, or a mindset strategy to stay resilient during stressful shifts. Why This Podcast? Because nursing school is hard—and the transition to practice can feel overwhelming. STAT Stitch Deep Dive bridges the gap between theory and bedside, helping you connect what you’re learning in your textbooks to the realities of patient care. You’ll get evidence-based content delivered in a friendly, conversational style that feels more like a study group than a lecture. Who Should Listen? Nursing students (ADN, BSN, accelerated, or bridge programs) Pre-nursing students preparing for the rigors ahead New graduates in their first year of practice Nurses preparing for the NCLEX or refreshing their knowledge Anyone passionate about nursing education, patient safety, and the art of caring beyond the bedside. This podcast is for anyone searching for nursing school tips, NCLEX prep, clinical practice advice, study hacks for nurses, nursing student motivation, bedside nursing skills, pathophysiology explained, pharmacology made simple, nursing management strategies, and the realities of life as a nurse. At its core, STAT Stitch Deep Dive: Beyond the Bedside is about stitching together knowledge, experience, and humanity. It’s not just about surviving nursing school—it’s about thriving as a future nurse who can think critically, act compassionately, and manage confidently at the bedside. So if you’re ready to go beyond memorization, beyond the stress, and beyond the bedside—hit play, subscribe, and join the conversation. Because in nursing, every detail matters. And here, we stitch them together.

STAT Stitch Deep Dive Podcast Beyond The Bedside is a education podcast hosted by Unknown Host, with 0 episodes on record and a Required Pod Score of 84. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Unknown Host hosts STAT Stitch Deep Dive Podcast Beyond The Bedside, a education show with 0 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  STAT Stitch Deep Dive Podcast Beyond The Bedside

  CC Pharm | Midazolam

  Aug 19, 202621 minS7

  Midazolam (Versed) 80/20 Clinical Summary Classes: Benzodiazepine sedative/hypnotic, anesthetic, anxiolytic, anticonvulsant. Mechanism: Enhances GABA-A receptors, increasing GABA affinity and opening chloride channels. This hyperpolarizes cell membranes, preventing excitation. Has twice the receptor affinity of diazepam. Pharmacokinetics: Metabolized by CYP3A4 to active, equipotent alpha-hydroxymidazolam. 97% protein-bound. Excreted via urine. IV: Onset 1.5–5m, duration 30–45m. Tissue accumulation in long infusions delays awakening. IM: Onset 5m, peak 15–30m. PO: Onset 10–30m, duration 40–70m, ~36% bioavailability. Intranasal (Nayzilam): Bioavailability 44–55%. Nasal burning lasts ~30s. Buccal/Rectal (Off-label): Onset is 10–30m; duration 40–90m. Black Box Warning & Complications Boxed Warnings: Requires specialized care setting, experienced clinician, and continuous cardio-respiratory monitoring. Profound risk of respiratory depression, apnea, arrest, and hypoxic encephalopathy/death. Coadministration with opioids or other CNS depressants severely increases risks of profound sedation, respiratory depression, coma, or death. Adverse Effects: Respiratory depression (8–23.3%), apnea (2.8–15.4%), severe hypotension, laryngospasm, bronchospasm, bradycardia, cardiac arrest. 80/20 Clinical & Nursing Pearls Monitoring: Continuously monitor respiratory effort and oxygenation (pulse oximetry) to detect hypoventilation or apnea early. Slow IV Push: Administer over ≥2 minutes; wait ≥2 minutes to assess effects before redosing. Avoid rapid push in neonates (risk of severe hypotension, hypoventilation, seizures). Antidote: Flumazenil must be immediately available to reverse respiratory depression. Note: Flumazenil can precipitate life-threatening seizures in chronic benzodiazepine users. Gradual Taper: Do not abruptly stop after continuous use (>1–2 weeks); taper gradually to avoid acute withdrawal (seizures, status epilepticus). Pediatric & Neonatal Safety: Preterm neonates have significantly slower clearance. Standard infusions are not recommended for preterm neonates Renal/Hepatic: Half-life is prolonged in renal impairment; pediatric doses must be reduced by 25% (GFR 10–29) or 50% (GFR Why Choose This Drug? Preferred for rapid-onset, short-duration procedural sedation, amnesia, and acute seizure control (drug of choice for emergent IM seizure therapy)

  ListenShow Notes
• 

  STAT Stitch Deep Dive Podcast Beyond The Bedside

  CC Pharm | Nitroprusside

  Aug 19, 202619 minS7

  Sodium nitroprusside is an ultra-potent, direct-acting peripheral vasodilator characterized by rapid hemodynamic action and highly toxic metabolites. This 80/20 summary distills its essential clinical, pharmacological, and nursing guidelines: 1. Mechanism & Hemodynamic Effects Mechanism: Direct action on arterial and venous smooth muscle ; myocardial contractility is unaffected. Hypertension: Reduces afterload and causes venous pooling, decreasing arteriolar resistance. Heart Failure: Improves left ventricular performance, increasing cardiac index, cardiac output, and stroke volume while slowing heart rate. 2. Dosing & Clinical Administration Onset & Duration: Rapid onset ( 1-2 mins ); effects persist for 1-10 mins after discontinuation. Titration: Confirm drug effect for 5 minutes before titrating to a higher dose. Dosing (Adults): Hypertensive Emergency: Start 0.3-0.5 mcg/kg/min ; titrate by 0.5 mcg/kg/min every 5 mins. Max: 10 mcg/kg/min for 10 mins. Acute Heart Failure: Start 0.1-0.3 mcg/kg/min . Max: 10 mcg/kg/min (doses >400 mcg/min have no added benefit). Mitral Regurgitation: Start 15 mcg/min, titrate every 2 mins to reduce mean arterial pressure by 10-20 mmHg. Preparation & Administration: Dilute 50 mg in 250–1000 mL of 5% Dextrose (D5W) . Never give direct IV injection. Solution is clear, colorless to red/brown; discard if blue, green, or bright red . Protect from light during administration with an opaque sleeve. Do not run other drugs in the same solution. 3. Boxed Warning: Cyanide & Thiocyanate Toxicity Cyanide Toxicity: Metabolism produces dose-related cyanide. Doses >2 mcg/kg/min exceed normal clearance. Buffering is exceeded in at the max 10 mcg/kg/min rate. Action: Discontinue and consider sodium nitrite and sodium thiosulfate . Thiocyanate Toxicity: Cyanide converts to thiocyanate via mitochondrial rhodanase (renal half-life: 3 days). Life-threatening at 200 mg/L . Monitor plasma levels if cumulative doses exceed 7 mg/kg/day . Organ Impairment Risk: Hepatic disease: High susceptibility to cyanide toxicity. Renal Impairment: eGFR (Anuria: limit to 1 mcg/kg/min ). 4. Nursing Interventions Monitoring: Mandatory continuous blood pressure monitoring, preferably via an intraarterial pressure sensor . Monitor urine output in heart failure. Safety: Use a volumetric infusion pump . Watch for hypotension, methemoglobinemia, bradycardia, or metabolic acidosis.

  ListenShow Notes
• 

  STAT Stitch Deep Dive Podcast Beyond The Bedside

  CC Pharm | Dobutamine

  Aug 19, 202622 minS7

  Dobutamine is a direct-acting parenteral sympathomimetic inotrope . It primarily acts as an agonist at beta1-adrenergic receptors (with minor beta2 and alpha1 stimulatory effects) to increase myocardial contractility, stroke volume, and cardiac output . Unlike dopamine, it does not stimulate dopaminergic receptors or release norepinephrine. It has comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects , and minimally affects pulmonary vascular resistance. Primary Indications & Clinical Dosing: Low Output States: Used for short-term treatment of cardiac decompensation due to depressed contractility from organic heart disease, cardiac surgery, congestive heart failure, cardiogenic shock, or septic shock. Continuous IV Dosage: Initiate adults, children, and neonates at 0.5 to 1 mcg/kg/min , titrating to a usual dose of 2 to 20 mcg/kg/min based on response. Rates >20 mcg/kg/min may cause tachycardia or ectopy; 40 mcg/kg/min is rarely required. Diagnostics: Used in dobutamine stress echocardiography starting at 5 mcg/kg/min, titrating up to 40 mcg/kg/min. Special Populations: No dose adjustments are needed for renal or hepatic impairment. Critical Administration Rules: Dilution & Infusion: Must be diluted before use (maximum concentration 5,000 mcg/mL ; standard adult concentration is 4,000 mcg/mL). Infuse using a controlled device, preferably into a large vein . Incompatibilities: Incompatible with sodium bicarbonate or strong alkaline solutions . Do not infuse dextrose-containing dobutamine through the same line as blood due to risk of pseudoagglutination/hemolysis. Physical Stability: Premixed bags in 5% Dextrose may turn pink over time due to slight oxidation, which does not impact potency. Intraosseous (IO): Not FDA-approved, but the same dose can be given via IO route during CPR if IV access is unfeasible. Pharmacokinetics & Safety Profile: Rapid Action: Infused intravenously, it has an onset of 2 minutes and a half-life of ~2 minutes . Severe Adverse Reactions: Can cause ventricular tachycardia, arrhythmia exacerbation, pulmonary edema, skin necrosis, and anaphylactoid reactions . Moderate Reactions: Includes hypertension, angina, palpitations, dyspnea, and premature ventricular contractions . Dosage titration must be guided closely by systemic blood pressure, heart rate, urine flow, and ectopic activity.

  ListenShow Notes
• 

  STAT Stitch Deep Dive Podcast Beyond The Bedside

  CC Pharm | Milrinone

  Aug 19, 202636 minS7

  Core Profile & Mechanism Milrinone is a parenteral positive inotrope and vasodilator with selective phosphodiesterase III (PDE3) inhibitor activity . By preventing cyclic adenosine monophosphate (cAMP) breakdown in cardiac and vascular muscle cells, it increases myocardial contractility, causes vasodilation, and improves diastolic relaxation (lusitropy) . This dual action reduces preload, afterload, and systemic vascular resistance with little to no chronotropic activity. Therapeutic effects occur at plasma levels of 100 to 300 ng/mL. Primary Indications Milrinone is used for the short-term treatment of acute heart failure and other low cardiac output states like cardiogenic shock or post-cardiac surgery low cardiac output syndrome (LCOS). It can provide long-term palliative support in stage D heart failure patients awaiting transplant or mechanical circulatory support. Off-label uses include pediatric septic shock or postresuscitation stabilization, cerebral vasospasm after aneurysmal subarachnoid hemorrhage, and persistent pulmonary hypertension of the newborn (PPHN) with poor nitric oxide response. Dosing & Administration Adult HF Dosing: A 50 mcg/kg IV loading dose over 10–60 minutes (though heart failure guidelines do not recommend a bolus), followed by 0.125 to 0.75 mcg/kg/minute continuous infusion . Renal Adjustments: Elimination is primarily renal (83% excreted unchanged in urine, half-life of 2.4 hours). For CrCl ≤ 50 mL/min, the adult continuous infusion rate must be adjusted down sequentially from 0.43 mcg/kg/min (CrCl 41–50) down to 0.2 mcg/kg/min (CrCl ≤ 5). Pediatric rates also require reductions for CrCl Administration Safety: Standard infusion is 200 mcg/mL, diluted in 0.45% or 0.9% NaCl or 5% Dextrose, run via a controlled device. It is not FDA-approved for intraosseous use, but the same doses can be given IO if IV access is unavailable. Critical Safety & Adverse Reactions Incompatibilities: Milrinone must never be co-administered with furosemide , as precipitation occurs immediately in the same line. It also cannot be given simultaneously with blood. Arrhythmias & Monitoring: Continuous ECG monitoring is mandatory . Milrinone carries a substantial risk of serious ventricular arrhythmias (VT up to 12%, VF 0.2%), atrial flutter/fibrillation (up to 8%), supraventricular tachycardia, and premature ventricular contractions. Hypotension & Other Risks: Hypotension occurs in 2.9% to 10.7% of patients. To reduce this risk, clinicians often avoid the loading dose in septic shock and neonatal PPHN. Thrombocytopenia is a delayed reaction occurring in up to 58% of patients.

  ListenShow Notes
• 

  STAT Stitch Deep Dive Podcast Beyond The Bedside

  CC Pharm | Norepinephrine

  Aug 19, 202624 minS7

  Norepinephrine (Levophed) 80/20 Summary Action & MOA: Direct α -agonist causing potent vasoconstriction . Modest β 1​ activity triggers cardiac stimulation at lower doses; vasoconstriction dominates at higher doses. Elevated SVR triggers reflex vagal bradycardia (slowing HR). Coronary flow increases without raising myocardial oxygen demand. Uses: First-line for septic shock , sepsis, acute hypotension, cardiogenic shock. Alternative in hepatorenal syndrome (with albumin). Complications: Tissue necrosis (extravasation), bradycardia , lactic acidosis , pulmonary edema , hypertension , and local hypoxia . Administration & Dilution: Dilution: Standard: 4mg in 1,000mL . Preferred: D5W/D5NS (dextrose protects against oxidation). Saline alone stable up to 16mcg/mL, though FDA discourages. Adult standard: 16, 32, 128mcg/mL . Incompatibility: Do not mix with alkaline solutions (e.g., bicarb). Reject if pinkish/discolored or has precipitate. Route: Large vein infusion ; transition to central line ASAP . Avoid leg veins in elderly. Monitoring: BP every 2 mins initially, then every 5 mins . Check site frequently for free flow/extravasation. Weaning: Reduce rate gradually ; avoid abrupt withdrawal to prevent rebound hypotension. Extravasation Antidote: Infiltrate ASAP (within 12h) with phentolamine 5-10mg in 10-15mL NS. Pharmacokinetics: Onset ; steady-state 5 mins ; duration . Half-life ~2.4 mins ; metabolized by COMT/MAO. Why Choose It? Preferred in septic shock; raises MAP/SVR with less tachycardia than dopamine , sparing oxygen demand. Final 80/20 Review The 20% to Absolutely Know: Hypovolemia First: Correct fluid deficit before starting norepinephrine. Central Line Priority: Transition to central line ASAP to mitigate necrosis risk. Phentolamine for Extravasation: Immediate local infiltration reverses ischemia. Dextrose Over Saline: Dextrose-containing diluents prevent oxidation. Incompatible with Bicarb: Inactivated in alkaline solutions. If I Remember Nothing Else: Norepinephrine is the first-line vasopressor for septic shock. With a

  ListenShow Notes

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.